(Tagrix) is the 1st and only drug of its kind approved by USFDA for the
treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell
Lung Cancer (NSCLC) patient with T790M mutation. Therapeutic indications TAGRIX
is indicated for the treatment of adult patients with locally advanced or
metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive
non-small cell lung cancer (NSCLC).